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Aptamersareshortnucleicacidsthatbindtodeﬁnedtargetswithhighaﬃnityandspeciﬁcity.Theﬁrstaptamershavebeenselected
about two decades ago by an in vitro process named SELEX (systematic evolution of ligands by exponential enrichment). Since
then, numerous aptamers with speciﬁcities for a variety of targets from small molecules to proteins or even whole cells have been
selected. Their applications range from biosensing and diagnostics to therapy and target-oriented drug delivery. More recently,
selections using complex targets such as live cells have become feasible. This paper summarizes progress in cell-SELEX techniques
and highlights recent developments, particularly in the ﬁeld of medically relevant aptamers with a focus on therapeutic and drug-
delivery applications.
1.Introduction
Aptamersareshortnucleicacids(typically12–80nucleotides
long) capable of speciﬁc and tight binding to their target
molecules. The term aptamer is derived from the Latin word
aptus (ﬁtting) and the Greek word meros (part). Aptamers
are selected by a process called SELEX (systematic evolution
ofligandsbyexponentialenrichment),whichwasestablished
independently by Ellington and Szostak [1], Tuerk and Gold
[2], and Robertson and Joyce [3] in 1990. A typical SELEX
experiment starts with a library of up to 1015 random
oligonucleotides,whichcanbeDNA,RNA,ormodiﬁedRNA
(e.g., 2 -OMe or 2 -F). Some members of this enormous
library are anticipated to bind a desired target. The key step
of the SELEX procedure is to eﬃciently separate those few
from the nonbinding species. Selected nucleic acids are then
ampliﬁed and used for further selection rounds. A successful
SELEX experiment will usually result in a collection of
aptamers, which can subsequently be cloned and tested
individually for their binding properties.
The possible aptamer targets show a great diversity rang-
ing from small molecules, like organic dyes [4], amino acids
[5] or antibiotics [6], peptides [7], proteins [8], and viruses
[9]towholecells[10].Thedissociationconstants(Kd values)
of aptamer-target complexes are comparable to those of
antibodies and can reach the picomolar range. In addition,
aptamers exhibit the following interesting features, which
set them apart from antibodies: they are selected entirely
in vitro, their synthesis has been automated, and they can
easily be chemically modiﬁed [11]. Furthermore, they can be
storedandshippedwithoutproblems,becausethestabilityof
DNA aptamers, in particular, is almost inﬁnite. Importantly,
they are not immunogenic. Due to their binding properties,
aptamers have become useful tools for diagnostic and
therapeutic applications [12, 13].
The ﬁrst representative of an aptamer drug is Macugen, a
highly modiﬁed RNA aptamer for treatment of age-related
macular degeneration (AMD), which has been released in
2004 [14].
In this paper, we are focusing on recent developments
in the selection of aptamers for complex targets and their
application in diagnostics and therapy. We are emphasizing
the potential of cell-based aptamer selections (cell-SELEX)
as a means to enrich binders to live cells and highlight the
potential of recent technical advances.
2.Aptamersfor Intra-andExtracellular
Targets and Their Application
Alternatively: for each class of targets, aptamers show outs-
tanding characteristics. For small molecules, aptamers were2 Journal of Nucleic Acids
found that discriminate between closely related targets, such
as caﬀeine and theophylline [15], diﬀering by a single methyl
group, or adenosine triphosphate and adenosine monophos-
phate (diﬀering by their 5 -phosphorylation state) [16].
These aptamers have been successfully used as diagnostic
tools and have been recently reviewed [17].
Nucleic acid-binding proteins, like Tat [18]a n dR e v[ 19]
of HIV-1, were found to be excellent protein targets yielding
high-aﬃnityaptamers.However,numerousexamplesproved
that nucleic acid binding is not a required target property
for the selection of tightly and speciﬁcally binding aptamers.
Several examples will be mentioned in this paper. There
are many ways of classifying aptamer targets into diﬀerent
groups. Here, we want to distinguish between intracellular
and extracellular targets.
Intracellular targets are diﬃcult to address in living cells,
because cytosolic delivery of aptamers, so-called intramers,
in suﬃcient quantities is not facile. The problem becomes
even harder for the delivery of aptamers in vivo.M o s t
of the applied methods rely on protocols established for
siRNA-transfection which have been recently summarized
in excellent reviews [20, 21]. Brieﬂy, lipofection-based me-
thods are technically simple but do not always yield suﬃ-
cient amounts of cytosolic aptamer to cause measurable
eﬀects. There are few examples for the successful delivery of
aptamers into cells. An aptamer speciﬁc for the N-terminal
part of cytohesin-2 was successfully transferred into cells
via lipofection and led to downregulation of the serum-
mediated MAPK activation [22]. Another example that
should be mentioned here is an EGFRvIII-binding aptamer
that intracellularly binds to the unglycosylated form of the
receptor, thereby disrupting its posttranslational modiﬁca-
tions [23].
The main alternative to lipofection is the intracellular
production of the intramers by generating appropriate ap-
tameroverproducingcelllines.Thisprocesshasbeenrealized
bytheapplicationofdiﬀerentexpressionvectors[24,25]and
by adeno- [26] or vaccinia-virus-based expression systems
[27]. However, the generation of stably transfected cell
lines is time consuming and of limited use for therapeutic
applications. These diﬃculties may explain why there is a big
gap between the number of aptamers available for intracel-
lular targets and the number of successfully used intramers.
Consequently, there is a concern whether intramers are suit-
able therapeutic agents in vivo.As m a r tw a yt oc i r c u m v e n t
the aptamer delivery problem is to ﬁnd cell-permeable inhi-
bitory small molecules interfering with the aptamer-protein
interaction by aptamer displacement screening [28].
Apart from aptamers for intracellular molecules, a var-
iety of aptamers has been selected that bind extracellular
proteins. The latter aptamers have the big advantage that
they can be administered intravenously or subcutaneously.
We can distinguish between shedded and cell-surface bound
targets. Only the latter are within the scope of this paper.
In the case of extracellular targets, aptamer stability be-
comes a major issue. Therefore, stabilized RNA (e.g., by 2 -
O-methyl or 2 -ﬂuoro modiﬁcations [29–32]) or DNA is
preferable when extracellular proteins are targeted. Even
then, degradation and clearance is inevitable, and repeated
administration will be required until treatment is complete.
3.Cell-SpeciﬁcAptamers
Aptamers for extracellular targets have high potential for
diagnostic and therapeutic applications. For diagnostics,
their ability to diﬀerentiate among diﬀerent cell types, name-
ly, between tumor cells and normal cells, is highly inter-
esting. More specialized aptamers can even be applied to
distinguish between diﬀerent types of cancers. In therapy,
aptamers for extracellular targets can be used directly as
eﬀectors(activatorsor inhibitors) or indirectly asvehiclesfor
drug delivery.
Surfaces of live cells and parasites represent very complex
and convoluted targets. Although it is clear that the cell sur-
facecontainsmanyrecognitionelements,forexample,tumor
markers in the case of cancer cells, its exact composition
is unknown. Subtle diﬀerences in cell surface compositions
can be very important and may be associated with the dif-
ferentiation of cells and the onset of malignancies. Analyzing
these changes and elucidating the exact composition of
diﬀerent cell types can yield important insights into the
molecular details associated with these transformations.
However,analysisofthemolecularcomposition(e.g.,bypro-
teinsequencingandmassspectrometricidentiﬁcation)isnot
suﬃcient to identify binders capable of targeting speciﬁc cell
types.
Cell-SELEX is an evolutionary approach, and thus allows
the selection of aptamers even without prior knowledge of
speciﬁc targets [33–35]. In theory, cell-SELEX may generate
aptamers for multiple targets in parallel. Another beneﬁt
of the cell-SELEX process is that it generates aptamers
for accessible cell-surface markers. Aptamers can, therefore,
speed up the discovery of new biomarkers that are per se tar-
getable.
Of course, several cell-surface markers that can be used
as target molecules in the traditional SELEX process have
already been identiﬁed. Using puriﬁed proteins as tar-get
molecules certainly raises the odds of obtaining ap-tamers
for this exact target molecule. However, cell-surface proteins
tend to be membrane bound and often cannot be easily
puriﬁed. In many cases, recombinant production and puri-
ﬁcation of extracellular domains is possible, but there is
a concern whether the domain will still adopt the native
conformation. In the worst case scenario, one could select
aptamers that will only bind to the puriﬁed protein or
protein domain and do not recognize the native form
on living cells. This risk can be eliminated using cell-
SELEX. Here, all the cell-surface molecules are presented
in their natural surrounding and native conformation and,
moreover, contain possible posttranslational modiﬁcations.
4.RecentAdvancesinCell-SELEX
4.1. Diﬀerent Ways of Obtaining Cell-Speciﬁc Aptamers.
There has been a long-standing interest in the selection of
aptamers for complex targets. Already in 1998, Gold andJournal of Nucleic Acids 3
coworkers used human red blood cell membranes as a model
system to determine if SELEX could be used for a complex
mixture of potential targets [36]. Aptamers for multiple
targets were generated simultaneously during the selection
process, and the binding aﬃnities of these aptamers for
their targets turned out to be comparable to those found in
similar experiments with pure targets [36]. Using a second-
ary selection scheme (deconvolution SELEX), the authors
rapidly isolated the aptamers for targets of special interest
within the mixture.
In many cases, binding to a speciﬁc cell-type can be
achieved by selecting aptamers for an abundantly presented
protein on the cell-surface using traditional protein SELEX.
Subsequently,theselectedaptamershavetobetestedfortheir
abilitytobindthenativeproteinpresentedonthecellsurface.
One example is the in vitro selection of RNA aptamers using
recombinantL-selectinastargetmolecule[37].Theresulting
aptamersboundL-selectinwithabout105 timeshigheraﬃn-
ity than the conventional oligosaccharide ligand sialyl Lewis
X[ 37]. The nuclease stabilized aptamers showed calcium-
dependent binding to native L-selectin on peripheral blood
lymphocytes and blocked L-selectin-dependent interactions
with the natural ligands on high endothelial venules. In a
diﬀerent approach, also DNA aptamers were selected with
puriﬁedL-selectin.Theseevenshowedeﬀectsonlymphocyte
traﬃcking in vivo [38].
Chen et al. selected RNA aptamers for the extracellular
domain of the human epidermal growth factor receptor-
3 (HER3) produced in insect cells and demonstrated that
the aptamers interfere with receptor activation in MCF7
cells [39]. Another example for this strategy is the selection
of 2 -F-modiﬁed aptamers using murine OX40 human IgG
Fc fusion protein, a member of the tumor necrosis factor
receptor superfamily [40].
Although the aforementioned examples were successful,
it would be preferable to use the native form of the cell
surface protein directly. However, cell surfaces are very
complex targets. If aptamers for a speciﬁc target molecule
within the cell surface are desired, cell-SELEX bears the
risk to select aptamers for molecules diﬀerent from the de-
sired target. Therefore, some laboratories have combined
selections using puriﬁed target proteins with cell-SELEX.
Examples include aptamers for E-selectin and tenascin-C: E-
Selectin is a cell adhesion molecule presented only on endo-
thelial cells activated by cytokines. Mann et al. obtained thio-
aptamers binding to endothelial cells presenting E-selectin
[41]. Tenascin-C is an extracellular matrix protein that is
overproduced during tissue remodeling processes, including
tumor growth. Hicke et al. performed protein SELEX, cell-
SELEX, and a crossover of both and selected aptamers with
Kd values in the low nanomolar range [42].
Although both, the traditional SELEX and a combined
approachwith cell-SELEX,havebeen successfullyapplied for
known targets, they do not exploit the full range of possi-
bilities that cell-SELEX has to oﬀer. If live cells are used,
there is no need for prior information of the cell surface
composition—a true asset. Figure 1 shows a schematic cell-
SELEX process including the most common separation
methods, which are centrifugation of cells in suspension,
washing of adherent cells, and ﬂuorescence activated cell
sorting (FACS).
Ascomplextargetforacell-SELEX,HomannandG¨ oring-
er used live Trypanosoma brucei, a sleeping sickness causing
protozoan parasite [43]. Nonbinding nucleic acids were
removed by repeated cycles of washing and centrifugation.
Finally, they identiﬁed RNA aptamers speciﬁc for a 42-kDa
protein located in the parasite’s ﬂagellar pocket. Bruno and
Kiel selected DNA-aptamers for diﬀerent spores such as
Anthrax or Bacillus thuringiensis [44].
Blank et al. used endothelial cells as targets and selected
DNA aptamers that could be used as histological markers of
microvesselsinbraintumors[45].Partitioningofboundand
unbound ssDNA molecules was done by centrifugation. The
progress of the selection as well as the binding properties of
individual aptamers were analyzed by FACS.
Gold and coworkers perforemed cell-SELEX using the
tumor cell line glioblastoma U251 as target. They selected
DNA aptamers for tenascin-C by simply incubating the
nucleic acids with cell monolayers in serum-free medium
a n dr e p e a t e dw a s h i n gs t e p s[ 46].
This technique was also used by Tan and coworkers who
publishedmultipleaptamersthatboundselectivelytocertain
cancer cell lines [47]. To do so, they performed a counter
selection with a control cell line before the actual incubation
step to remove cell matrix binders. Table 1 gives an overview
of cell lines used for live cell-SELEX.
4.2. Technical Challenges and Advances in Cell-SELEX. Until
recently, most technical advances of the SELEX procedure
focused on improving the individual steps of the process,
in particular the actual selection step, in order to make
the generation of aptamers as fast and eﬃcient as possible.
The main points for optimization are automation, separa-
tion, counter selection, and the partitioning of dead cells.
Automation of the SELEX process was introduced by Elling-
ton and coworkers [48]. As a consequence, selection times
were signiﬁcantly reduced. Since then, aptamers are also
com-mercially available.
Furtheroptimization is requiredtoavoidmatrix-binding
species within an in vitro selection. In the classical protocol
for SELEX, the target protein is immobilized on a solid sup-
portsuchasagarose,sepharose,ormagneticbeads.Thelatter
havebecomeparticularlypopular duetolowmatrix binding.
Alternative separation protocols include ﬁlter binding and
innovative approaches such as capillary electrophoresis [49].
As mentioned above, the classical approaches have been used
successfully to select aptamers for cell-surface proteins that
recognize speciﬁc live cells.
Target immobilization however, is not compatible with
live cells. Most cell-SELEX protocols so far separate binding
from nonbinding nucleic acids by washing (adhesive cells)
or centrifugation (cells growing in suspension). For obvious
reasons it is not easy to enrich exclusively the desired target-
binding species in complex target SELEX approaches, and
therefore, counter selections have to be applied in most cases
(Table 1).
Cerchia et al. performed even two of those counter selec-
tions, one with suspended parental Pc12 cells and a second4 Journal of Nucleic Acids
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Figure 1: Cell-SELEX. (1) Target cells are incubated with a complex library consisting of up to 1015 individual single stranded DNA
molecules (ssDNA). (2) The separation of cell-binding nucleic acids from nonbinding species can be performed by diﬀerent methods:
FACS (2a), centrifugation (2b) or washing (rinsing) steps (2c), respectively. (3) Cell-binding DNA molecules—aptamers—are eluted and
(4) subsequently ampliﬁed by PCR using two speciﬁc primers. The 5 -end of the reverse primer carries a biotin. Additionally, a ﬂuorescently
labeled forward primer is used for PCR, if FACS is used for separation. After strand displacement the enriched DNA library is used for
further selection rounds. This cell-SELEX procedure ends up with aptamers that bind speciﬁcally to the surface of target cells.
Table 1: Cell-lines used for cell-SELEX and for corresponding counter selection. The column “When?” indicates whether counter selection
was performed before (B) or after (A) the selection, or not at all (—).
Selection cell line Abbreviation Counter selection Abbreviation When? Lit.
T-cell line, human ALL CCRF-CEM B-cell line, human Burkitt’s
lymphoma Ramos A [54]
Carcinoma; small-cell lung cancer NCI-H69 Carcinoma; large-cell lung cancer NCI-H661 A [55]
Mouse liver hepatoma cell line BNL 1ME A.7R.1
(MEAR) Normal mouse liver cell line BNL CL.2 A [56]
Acute myeloid leukemia HL60 Acute promyelocytic leukemia NB4 A [57]
Human lung carcinoma cells
infected with vaccinia virus A549 Human lung carcinoma cells
without infection A549 A [58]
Pheochromocytoma of the rat
adrenal medulla expressing
human RETC634Y mutant
Pc12/MEN2A
Pheochromocytoma of the rat
adrenal medulla parental cells
followed by cells expressing
human RETM918T mutant
Pc12 and
Pc12/MEN2B B[ 50]
B-cell line, human Burkitt
lymphoma Burkitt lymphoma None, but FACS to sort out dead
cells —[ 10]
Human glioblastoma U251 U251 None — [46]
Endothelial cell line YPEN-1 YPEN-1 N9 microglial cells B [45]Journal of Nucleic Acids 5
onewithadherentPc12/MEN2Bcellsbeforeincubatingtheir
2 -F-modiﬁed RNA library with Pc12/MEN2A cells, the
actual selection target presenting the human RETC634Y mu-
tant receptor [50].
Most people who have actively selected aptamers are
familiar with the problems of matrix binders. The logic
behind this problem is apparent and has been called the
ﬁrst law of directed evolution: “You get what you select for”
[51]. Since in every cycle, multiple selection pressures are in-
volved, it is not surprising that artifacts may arise. It can be
anticipated that this problem becomes more serious when
using complex surfaces of cells or spores as selection target.
To make things even worse, there is an additional pro-
blem for cell-SELEX with live cells: in every cell preparation
also dead cells are present. Dead cells show strong, sequence-
independent aﬃnity for nucleic acids [52]. They cannot be
removed by traditional methods like washing or centrifuga-
tionandthusleadatleasttoanineﬃcientselectionprocessor
even to failure of the experiment [53]. Sample preparation is,
therefore,veryimportant. Theseproblemsmaybethe reason
whycell-SELEXhasnotyetbecomeawidelyusedmethodfor
the generation of cell-speciﬁc aptamers.
The above issues were addressed in a recent publication
by the laboratories of Mayer and Famulok [10]. They used
FACS to remove the fraction of dead cells and to select
aptamers binding to live cells. Thus, they obtained aptamers
speciﬁc for B-cells that were able to diﬀerentiate between dif-
ferent cell subpopulations.
5. Cell-SpeciﬁcAptamersfor Afﬁnity
PuriﬁcationandDiagnostics
There are numerous applications for aptamers, including
aptamers as sensors, as inhibitors, as diagnostics, as thera-
peutics, and as delivery agents. There are excellent reviews
dealing with these topics, forexample, [17].Here,we wantto
focus on the application of cell-speciﬁc aptamers for aﬃnity
puriﬁcation, diagnostics, and most importantly therapy.
The ﬁrst and obvious application of cell-speciﬁc apta-
mersistheiruseforaﬃnitypuriﬁcation.Aﬃnitypuriﬁcation
has been described with several aptamers selected for single
targets [59, 60]. More interesting puriﬁcation tools are apta-
mers with aﬃnity for complex targets like cells. The speciﬁc
target molecule may be identiﬁed afterwards using mass
spectrometry.
Using this approach Blank et al. took advantage of an
aptamer that binds to tumor microvessels for aﬃnity puri-
ﬁcation and identiﬁed pigpen as the target protein [45]. The
above-mentioned aptamer selected for human glioblastoma
U251 cells was also used to identify the target protein
tenascin-C [46]. An inherent advantage of this aptamer-
based target puriﬁcation-identiﬁcation approach is that the
identiﬁed targets are per se addressable.
Tanandcoworkersusedseveraloftheircell-speciﬁcapta-
mers for extraction of speciﬁc cells from complex mixtures.
They reported aptamers for small-cell lung cancer (SCLC)
cells and used them in conjugates with nanoparticles to
isolate and enrich SCLC cells from mixed cell media [55].
The same laboratory developed a method for the rapid
collection and detection of leukemia cells based on an
aptamer for CCRF-CEM acute leukemia cells and two kinds
of nanoparticles (magnetic and ﬂuorescent). This dual ap-
proachallowedtargetcellextractionfromcomplexmix-tures
including whole blood samples as well as sensitive cell detec-
tion [61].
Aptamershavealsoalongtraditioninclassicaldiagnostic
applications, in analogy to antibodies. For the creation of
sensors, it is ideal to use a ligand-induced conformational
changetocreateasignal.Thishasbeenrealizedbydiﬀerential
dye binding, ﬂuorescence quenching, FRET, or coupling to
diﬀerent types of nanoparticles. Also, modular aptamer sen-
sors consisting of a recognition domain and a signaling apta-
mer have been constructed (for a review, see [62]). Re-cently,
a sensor based on a cell-speciﬁc aptamer was reali-zed by a
gold nanoparticle-aptamer conjugate on a lateral ﬂow device
that could be used for the detection of Ramos cells [63]. This
approach represents ﬁrst steps towards the de-tection of cir-
culating cancer cells.
6. Cell-Speciﬁc Aptamers for Therapy
Aptamers are not only a new and promising alternative
to antibodies in diagnostics. They may also be used in
therapy and medicine. For therapeutic applications, it is of
particular interest to selectively deliver drug molecules to
disease-related cells or tissues of interest thereby minimiz-
ing the exposure of these possibly harmful agents to sur-
rounding healthy tissues. This target-controlled transfer can
be achieved by conjugating desired drugs to carriers that
speciﬁcally interact with components (e.g., proteins) only
presented on the surface of pathologically relevant cells.
Cell-surface proteins are targeted by more than 60% of all
currently available drugs—underscoring their therapeutic
importance [64]. Receptors play the most prominent role
among these cell-surface proteins. They receive a signal,
transduce it viathe cellular membrane, and forward it inside
the target cell in many cases to ﬁnally trigger a cellular res-
ponse, such as gene expression.
As mentioned before, cell-SELEX can yield aptamers that
are able to interact with speciﬁc disease-related proteins
on cell surfaces. These aptamers are potential therapeutic
compounds because they may cause inhibitory as well as
stimulatory eﬀects. Furthermore, most cell-surface proteins
undergo recycling processes, such as ligand-induced inter-
nalization. This opens new strategies for aptamer-based
drugs. Aptamers binding to receptors that are subject to
internalization can be inﬁltrated into target cells, and thus
serve as vehicles for desired cargo molecules.
In the following sections, we will give an overview of
the current state of cell-speciﬁc aptamers. We have classiﬁed
the aptamers into three categories: aptamers eliciting (i) ago-
nistic or (ii) antagonistic eﬀects on the target protein as well
as (iii) aptamers as drug delivering agents.
6.1. Aptamers as Blocking Agents. Aptamers might be of ther-
apeutic relevance due to their inhibitory eﬀects on disease-
related cell-surface components. One promising approach6 Journal of Nucleic Acids
would be the application of aptamers acting on deregulated
processes in inﬂamed tissues or pathological vasculature
during angiogenesis.
In 2010, Mann et al. reported phosphorothioate-modi-
ﬁed aptamers binding to E-selectin on endothelial cells and
above all to the inﬂamed vasculature of human carcinomas
presenting E-selectin in high amounts on their cell surfaces
[41]. Selectins comprise a family of calcium-dependent cell
adhesion glycoproteins which can be subdivided into 3
groups: E-selectin that can be found in endothelial cells,
L-selectin on the surface of leukocytes, and P-selectin on
platelets and endothelial cells. All family members play cru-
cial roles during normal and abnormal inﬂammation pro-
cesses. Due to structural similarities, they are all able to
interact with speciﬁc carbohydrates (sialyl Lewis X and sia-
lyl Lewis A) on the surface of leukocytes thereby mediating
the contact of the leukocytes to the endothelial wall [70].
E-selectin levels are increased on the endothelial surface of
blood vessels within numerous inﬂammatory diseases, for
instance, rheumatoid arthritis and several types of cancer
[71]. Therefore, targeting E-selectin in inﬂamed tissues is a
therapeutically highly relevant strategy to prevent cell trans-
migration processes along endothelial tissues. Mann et al.
performed a two-step SELEX procedure (see above). In the
ﬁrst 10 SELEX rounds, puriﬁed recombinant E-selectin ser-
ved as target. Subsequently, the 14 obtained aptamers were
screened for binding to E-selectin presented on endothelial
cells. Only one of the aptamers named ESTA-1 exhibited
binding to cell surface bound E-selectin. Furthermore, this
aptamer inhibited the adhesion of sialyl Lewis X positive HL-
60 cells to E-selectin producing endothelial cells (Figure 2).
After intravenous administration, a distinct interaction of
the E-selectin-speciﬁc aptamers with tumor vasculature
could be highlighted in a breast cancer xenograft model [41].
Within the same month Gutsaeva et al. reported on the
application of the P-selectin binding RNA aptamer ARC5690
that contained 2 -ﬂuoro pyrimidine and 2 -methoxy purine
building blocks for increased nuclease stability. The aptamer
eﬀectively blocked the adhesion of circulating sickle red
blood cells (RBCs) and leukocytes to endothelial cells in
sickle cell disease (SCD) after injection into SCD mice [65].
Administration of the aptamer led to a decreased mortality
rate of the treated mice opening the possibility to use these
anti-P-selectin aptamers as potential anti-cell adhesion com-
pounds in sickle cell disease.
In1996,O’Connelletal.succeededinselecting2 -amino-
modiﬁed RNA aptamers binding to L-selectin-Ig chimera
(LS-Rg) [37]. The aptamers revealed a calcium-dependent
binding to native L-selectin on peripheral blood mononu-
clear cells (PBMCs). Moreover, the aptamers speciﬁcally in-
hibited the interaction of LS-Rg and of human PBMCs with
lymph node high endothelial venules that carry the natural
ligands of L-selectin. Nevertheless, there was one signiﬁcant
drawback: the aptamers possessed their highest aﬃnity at
4◦Ca n d2 2 ◦C. At 37◦C, the aﬃnity for L-selectin was
remarkably lower. Thus, these aptamers did not seem to be
par-ticularly suitable for in vivo applications [38].
Consequently, Hicke et al. reported on the selection of
DNA aptamers that did bind to L-selectin with nanomolar
aﬃnity [38]. These aptamers inhibited the L-selectin inter-
action with sialyl Lewis X. Additionally, the aptamers bound
speciﬁcally to human L-selectin on lymphocytes and neu-
trophilcells.TheDNAsinhibitedlymphocyterollingonacti-
vated endothelial cells in an in vitro ﬂow system. In vivo, the
aptamers prevented the homing of human lymphocytes to
lymph nodes in severe combined immunodeﬁciency (SCID)
mice.
Aside from adhesion molecules, also cytokines and their
respectivereceptors areinvolved in avariety ofinﬂammatory
diseases like osteoarthritis (OA), the most common degener-
ative joint disease, caused by cartilage loss in a joint [72].
The cytokine interleukin-17 in conjunction with one of its
receptors IL-17R is involved in the pathogenesis of OA. IL-
17R is a glycoprotein that displays a wide tissue distribution
and is a central mediator in inﬂammatory responses [66].
Following IL-17R activation multifunctional cytokines like
IL-1 and IL-6 are produced and enforce inﬂa-mmatory
processes.Chenetal.reportedonanovelcell-basedselection
method leading to DNA aptamers speciﬁc for IL-17R. The
authors used whole IL-17R presenting NIH3T3 cells as
t a r g e t sa n du n m o d i ﬁ e dN I H 3 T 3c e l l sa sn e g a t i v ec o n t r o lf o r
counterselection. Aptamer RA10-6 was able to interfere with
the interaction of IL-17 and IL-17R in vitro. After intra-
articular injections in OA mice the aptamers impeded syn-
ovialthickeningandinﬂammationincombinationwithcele-
coxib,asmallnonsteroidalanti-inﬂammatorydrug (NSAID)
often used in the treatment of osteoarthritis. Furthermore,
its administration led to a dose-dependent reduction of IL-
6 levels. In the future, it may be conceivable to addition-
ally administer RA10-6 to NSAIDs in standard therapies
for OA to circumvent high NSAID doses and associated
side eﬀects.
Aptamers binding to receptor tyrosine kinases (RTKs)
also reveal a high therapeutic potential. RTKs are cell surface
receptors that bind their ligands like growth factors or hor-
mones with high aﬃnity. Besides their role in the regulation
of common cellular processes, such as cell growth and dif-
ferentiation, RTKs are involved in the development and pro-
gression of many cancer types [73]. One example is the hu-
man epidermal growth factor receptor-3 (HER3), a member
of the type I RTKs. HER3 is catalytically deﬁcient and self-
associates in the absence of its ligand heregulin [74]. After
bindingofheregulintoHER3,heterodimerizationwithother
RTKs, especially HER2, occurs. Overproduction of both
HER2andHER3canbefoundinseveraltypesofcancer[75].
Chen et al. were able to select RNA aptamers binding HER3
in its oligomeric state [39]. One aptamer, A30, was further
investigated. It did not compete with heregulin for binding
to HER3 but inhibited heregulin-dependent tyrosine kinase
activity of HER2 and growth of MCF7 cells. Although the
inhibition mechanism could not be clariﬁed in detail, this
study demonstrates the potential of aptamers as anticancer
drugs.
Another RTK used as target for the enrichment of
aptamers was the human RET receptor tyrosine kinase
[50] (selection see above). One of the obtained aptamersJournal of Nucleic Acids 7
Table 2: Aptamers with inhibitory function on target molecules and corresponding selection strategies.
Target Aptamer Selection method Lit.
E-selectin Thiophosphate-mod. DNA Two-step selection using recombinant ES-Ig chimera and
testing on cells as target [41]
P-selectin 2 -amino- and 2 -methoxy-mod.
RNA
Traditional SELEX using recombinant mouse P-selectin as
target [65]
L-selectin 2 -amino-mod. RNA and DNA Traditional SELEX using recombinant L-selectin-Ig chimera
as target [37, 38]
IL-17R DNA Cell-SELEX using IL-17R presenting NIH3T3 cells as target,
unmodiﬁed NIH3T3 cells for counter selection [66]
HER3 RNA Traditional SELEX using the extracellular part of HER3 as
target [39]
RET 2 -F-mod. RNA
Cell-SELEX using RETC634Y receptor presenting
Pc12/MEN2A cells as target, Pc12 and Pc12/MEN2B cells for
counterselection
[50]
NgR RNA Traditional SELEX using the extracellular part of NgR-Fc
fusion protein as target [67]
CTLA-4 2 -F-mod. RNA Traditional SELEX using CTLA-4-Fc fusion protein as target [68]
gp120 2 -F-mod. RNA Traditional SELEX using puriﬁed recombinant gp120 as
target [69]
Tumor cell
Endothelium
E-selectin
sLex
Figure 2:Aptamersasblockingagents.Aptamers,inthiscasecomposedofphosphorothioates,selectivelybindtoE-selectinthatispresented
on the surface of human endothelial cells. The aptamers serve as antagonist for the interaction to sialyl Lewis X on HL-60 cells, a human
promyelocytic leukemia cell line, thereby inhibiting the adhesion of tumor cells by more than 75%.
bound to diﬀerent cell types presenting RET on their cell
surface.Theaptamerinterferedwithligand-inducedreceptor
dimerization or dimerization caused by activating mutations
within the receptor, and thereby inhibiting intracellular RET
signaling pathways.
In another study, aptamers were used to block the Nogo-
66 receptor (NgR) on axons after spinal cord injury [67].
Axon regeneration is usually prevented by three inhibitors
from the myelin sheath, which are ligands of NgR [76]. The
NgR-speciﬁcaptamersblockedthemyelin-derivedinhibitors8 Journal of Nucleic Acids
Table 3: Aptamers for cell-speciﬁc delivery of drug molecules.
Target molecule Aptamer Drug molecules linked or complexed with the
aptamer Lit.
PSMA 2 -F-modiﬁed RNA (1) siRNAs/shRNAs (1) [88–92]
(2) Protein toxin gelonin (2) [93]
(3) Dox (3) [94]
( 4 )Q D s ,S P I O No rg o l dN P sw i t hD o x ( 4 )[ 95–99]
(5) Pt(IV)-encapsulated PLGA-PEG NPs (5) [100]
gp120 2 -F-modiﬁed RNA siRNAs [101, 102]
Nucleolin DNA PDT agent TMPyP4 [103]
PTK7 DNA Dox [104]
TfR DNA L-iduronidase [105]
MUC1 DNA PDT agent chlorin e6 [106]
EGFR RNA Gold NPs [107]
IgM heavy chain DNA Micelle-like nanostructures [108]
by competing for binding to NgR [67] and fostered neurite
outgrowth of primary cultured neuronal cells. This re-
sult highlights the therapeutic potential of aptamers in
the treatment of myelin-associated inhibition of neuronal
regeneration.
Santulli-Marotto et al. developed a promising aptamer-
based strategy to inhibit the activation of an immune re-
ceptor. The authors selected aptamers speciﬁc for the T-
cell receptor CTLA-4 [68]. CTLA-4 (cytotoxic T lymphocyte
antigen-4) is a high aﬃnity receptor for the B7 family mem-
bers of immune regulatory ligands presented on activated T-
cells. This receptor exists in a dimeric form and is stimulated
by two molecules of the ligand protein B7-1 [77]. CTLA-
4 inhibits antitumor immunity. It transmits an inhibitory
signal to T cells, which reduces their ability to respond to
stimuli by enhancing the signaling threshold. As a result
higher amounts of signal molecules would be required for
further stimulation. Inhibitors of CTLA-4 (e.g., antibodies)
are potential agents to enhance T-cell anti-tumor immunity
[78]. CTLA-4-speciﬁc high aﬃnity aptamers enforced tumor
immunity in mice [68]. Tetramers of these CTLA-4-binding
aptamers showed even stronger inhibitory eﬀects on CTLA-
4f u n c t i o nin vitro and in vivo. These constructs seem to
be useful anti-tumor agents and regulators of the immune
system.
Similarly 2 -F-modiﬁed aptamers could be selected with
the potential to lower HIV-1 (human immunodeﬁciency
virus 1) infectivity by blocking gp120, a cell surface receptor,
both, on HIV-1 and on HIV-1 infected immune cells [69, 79,
80].Further developments and applications willbe discussed
later.
6.2. Aptamers as Stimulating Agents. In this section we will
focus on aptamers causing activating eﬀects by binding to
therapeutically relevant cell-surface proteins.
Recently, McNamara et al. introduced agonistic aptamers
speciﬁc for the costimulatory receptor 4-1BB, a member of
the tumor necrosis factor (TNF) receptor family [81]. This
receptor is presented on activated CD8+ T-cells and pro-
T-cell
OX40
TRAF-2
NF-κB
IKK
Transcriptional activation
Figure 3:Aptamersasstimulatingagents.DimerizedOX40-speciﬁc
RNA aptamers show activating eﬀects on the OX40 receptor in vitro
and in vivo. The OX40 receptor on the surface of activated T cells
undergoes receptor oligomerization and provides a costimulatory
signal for T cell activation. Downstream factors (e.g., TRAF-2, IKK
and NF-κB) of the signaling cascade are activated leading to an
enhanced proliferation of T cells and an increased anti-tumor im-
mune response.
longs the survival and expansion of CD8+ Tl y m p h o c y t e s
[82]. Since CD8+ T-cells play an important role in tumor
immunity, enhancing 4-1BBs costimulatory activity could
support anti-tumor immune responses. Indeed, agonisticJournal of Nucleic Acids 9
monoclonal antibodies against 4-1BB that had been systemi-
cally administered to mice ameliorated tumor immunity and
tumor rejection [83, 84]. Aptamers for 4-1BB represent an
attractive alternative because antibodies can be immuno-
genic in some cases and might cause problems in clinical
trials. The aptamers speciﬁcally bound to 4-1BB presented
on the surface of activated T cells [81]. Stimulation of
receptors of the TNF receptor family, including 4-1BB, often
involves oligomerization. Notably, the oligomerization could
beinducedbydimeric andmultimeric formsoftheaptamers
and triggered the activation of 4-1BB. Thus, the aptamer-
based di- and multimers acquired the ability to costimulate
T cells and induce tumor rejection in mice. As mentioned
above, there are aptamers that block CTLA-4 functions on
activatedT-cellsinvivoandenforcetumorimmunityinmice
[68]. Combinations of aptamers for CTLA-4 and 4-1BB may
even be better antitumor agents than each aptamer by itself.
Dollins et al. extended the approach of inducing receptor
multimerization by aptamers to trigger agonistic eﬀects.
They selected aptamers for the target molecule OX40 [40].
OX40, another member of the TNF receptor family, is pre-
sentedonthesurfaceofactivatedTcells.Bindingofitsligand
OX40L (OX40 ligand) causes receptor oligomerization. This
activation leads to an enhanced proliferation rate of T cells,
to an increased cytokine production, and to an intensiﬁed
anti-tumor immune response. After selection, Dollins et al.
converted the monomeric aptamers into receptor activating
dimers using a molecular scaﬀold (Figure 3). This aptamer
complex mimicked the OX40 ligand and induced OX40
multimerization and function both in vitro and in vivo in
a tumor immunotherapy approach. Systemic administration
of the agonistic aptamer complex showed a remarkable eﬀect
in the treatment of highly metastatic and aggressive types
of melanoma [40]. Both the 4-1BB and the OX40 aptamers
impressivelydemonstratedhowcell-surfacereceptorbinding
aptamers could be turned into receptor activating complexes
by di- or multimerization [40, 81]. These nucleic acid-based
agonists could become a new safe and powerful class of
therapeutically relevant eﬀectors.
Ar el a t eda p p r oac hc o m b i n edt w oD N Aa p t a m e r sf o rd i f -
ferenttumorassociatedtargets[85].Boltzetal.describedthe
generation of chimeric DNA aptamers that simultaneously
bound two surface receptors of immune cells and mediated
tumor lysis.
Speciﬁcally, one of the aptamers bound to the Fcγ
receptor IIIA also known as CD16α. CD16α belongs to
the immunoglobulin superfamily and is mostly presented
on natural killer cells but also on monocytes and certain
tissue macrophages, respectively. CD16α plays an important
role during the antibody-dependent cellular cytotoxicity
(ADCC). The recruitment of CD16α-positive NK-cells to
speciﬁc tumor cells could increase the antitumor-eﬀective
function during ADCC. The second aptamer bound to the
hepatocyte growth factor receptor (HGF-R) also known as
c-Met. The c-Met receptor belongs to the RTK family. As
mentioned above, RTKs are important regulators in cellular
processes and thus key players in the development and
progression of many cancer types [86]. The c-Met protein
is presented on epithelial cells, important for embryonic
development and overproduced in many tumors [85, 86].
Aptamers recognizing both, the CD16α and c-Met could
potentially recruit NK-cells to c-Met-positive tumor cells,
inducing ADCC and, therefore, acting as anti-tumor agents.
Boltz et al. generated high-aﬃnity aptamers for CD16α
and for c-Met and connected them by an oligonucleotide
linker. The resulting bi-speciﬁc aptamers mediated cellular
cytotoxicity, induced killing of NK cells and subsequently
speciﬁcally lysed tumor cells in ADCC assays. In the future,
the authors will expand these ﬁndings to in vivo experiments
using xenograft mouse models. Taken together the described
bi-speciﬁc aptamers illustrate the ability of nucleic acid-
based therapeutics to stimulate the lysis of tumor cells, a pro-
perty that opens up the possibility to serve as reagents in
cancer therapy.
6.3. Aptamers for Delivery of Toxic Payloads. Aptamers can
also serve as modules that selectively recognize and bind to
deﬁned cell types or tissues. By appending drug molecules,
the aptamers can be used to deliver cargo molecules to or
into speciﬁc cells or tissues of interest.
6.3.1. Prostate Speciﬁc Membrane Antigen (PSMA). One of
the best-studied aptamers binds to the prostate speciﬁc
membrane antigen (PSMA), a well-known tumor marker for
prostate cancer [87].
In 2002, Lupold et al. reported the selection of 2 -F-
modiﬁed RNA aptamers binding to the extracellular portion
of PSMA. Aptamer A10 and its truncated version A10-3
were able to bind PSMA presenting human prostate cancer
cells with high aﬃnity and served as a prostate speciﬁc tu-
mor cell marker [8]. The detection of speciﬁc endocytosis
of PSMA into cells via clathrin-coated pits suggested that
PSMA-speciﬁc aptamers might be potential drug delivery
vehicles [109]. Therefore, aptamer-drug chimeras were con-
structed. The idea was that the aptamers would speciﬁcally
recognize and bind to prostate cancer cells and then become
endocytosedtogetherwithPSMA—resultingindrugdelivery
to the target cells.
Several groups created chimeras consisting of small
interfering RNAs (siRNAs) and the PSMA-speciﬁc aptamer
A10 [88–91]. McNamara et al. used a completely RNA-based
approach by directly connecting the PSMA aptamer A10 at
its 3 -end with therapeutic siRNAs speciﬁc for plk1 and bcl-
2, two survival genes that are overexpressed in many human
tumors [89]( Figure 4) .T h ec h i m e r a sw e r es u p p o s e dt ob i n d
PSMA on target cells via the aptamer and to silence the
target mRNAs via the siRNA portions. Administration of
the chimeras to PSMA presenting cells indeed resulted in
endocytosis, gene silencing, reduced cell proliferation, and
ﬁnally cell death. Importantly, the chimeras did not aﬀect
cells that did not present PSMA. The next step was the
intratumoral application of the aptamer-siRNA chi-meras
into athymic mice that carried tumors derived from PSMA-
positive human prostate cancer cells. In these mice, the
chimeras indeed reduced tumor growth. The same experi-
ment was performed with mice bearing tumors from PSMA-
negative human prostate cancer cells. These tumors were10 Journal of Nucleic Acids
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Figure 4: Aptamers as drug delivery agents. Prostate speciﬁc membrane antigen (PSMA) is internalized into cells via endocytosis. PSMA-
binding RNA aptamers serve as drug delivery vehicles for small interfering RNAs (siRNAs, (a)). The siRNAs escape from the endosome, are
processed by Dicer and RISC, and lead to the degradation of target mRNAs. Furthermore, the aptamers can escort cytotoxic molecules into
prostate cancer cells like the ribosomal toxin gelonin (b), cisplatin encapsulated in organic PLGA-PEG-NPs (c), nanoparticles (NPs, gold,
iron oxide and quantum dots; (d)), or doxorubicin as a physical conjugate (e). For references see text.
not aﬀected by the chimeras. This strongly suggests that
the cellular uptake of the RNA ligands was highly eﬃcient
and speciﬁc for PSMA. The aptamer-siRNA chimeras were
further optimized by the same group [90]. The authors
truncated the aptamer portion and enhanced the silenc-
ing activity and speciﬁcity by incorporating modiﬁcations
within the siRNA molecules leading to a more eﬃcient
processing eﬀectivity of the RNAi machinery. The optimized
chimeras were systemically administered into athymic mice
bearing tumors from PSMA-positive human prostate cancer
cells leading to distinct tumor regression or anti-tumor
activity, respectively.
Chu et al. used another conjugation strategy between a
PSMA-speciﬁc aptamer and two diﬀerent siRNAs speciﬁc
for lamin A/C or GAPDH (Glyceraldehyde 3-phosphate
dehydrogenase) mRNAs [91]. Both the aptamer and the
siRNAs were chemically modiﬁed with biotin and bound to
tetrameric streptavidin in a 2:2:1 ratio. The resulting RNA-
protein complexes were cell type-speciﬁcally internalized
and caused down regulation of target genes and cell-death
of PSMA-presenting cancer cells. Wullner et al. created
multivalent aptamer-siRNA constructs to further increase
potency and anti-tumor capacity of the chimeras [88]. The
authors generated two diﬀerent bivalent chimeras consisting
of the anti-PSMA aptamer and siRNA speciﬁc for the EEF2
(eukaryotic elongation factor 2) mRNA. In one case, the
siRNAitselfservedaslinkerbetweentwoaptamermolecules,
whereas in the other case, siRNAs were attached to the 3 -
end of each aptamer. The increased valency of the aptamer-
siRNA chimeras enhanced cytotoxicity with respect to the
monovalent counterparts.
Very recently, Ni et al. used aptamer-shRNA chimeras
to inhibit DNA repair pathways in prostate cancer cells and
subsequently to enhance ionizing radiation (IR) therapyJournal of Nucleic Acids 11
[92]. The target mRNA of the shRNA was the catalytic
subunit of DNAPK (DNA-activated protein kinase, catalytic
polypeptide). DNAPK is a serine/threonine protein kinase
that is necessary for the double-strand break repair in DNA
[110]. Therefore, downregulation of DNAPK by aptamer-
shRNA chimeras should selectively sensitize PSMA-positive
cells to IR. Cell-speciﬁc delivery of the aptamer-shRNA chi-
meras to PSMA-positive LNCaP cells and to tumor models
led to reduced levels of DNAPK mRNA [92]. A combination
oftheapplicationofaptamer-shRNAchimerasandIRforthe
treatment of LNCaP tumor models resulted in an extended
reduction of tumor volume due to enhanced radiosensitivity.
Finally, the authors could also demonstrate high eﬃcacy of
the chimeras in human prostate tissue.
Apart from aptamer chimeras with siRNA, aptamers can
be fused to toxic proteins to deliver them into target cells.
This approach was realized by covalently linking a PSMA-
speciﬁc aptamer [93] to a gelonin derivative (Figure 4).
Gelonin is a ribosome-tackling toxin that cleaves a speciﬁc
glycosidic bond in rRNA subsequently disrupting protein
biosynthesis.Thisgeloninderivativelacksthetranslocational
domain and, in contrast to related toxins, is not translocated
per se into cells. In conjunction with the aptamer, however,
the gelonin variant was internalized into PSMA-presenting
tumor cells consequently destroying them. This unequiv-
ocally demonstrated the ability of the PSMA-aptamer to
deliver a therapeutically relevant toxin as payload into target
cells.
Chemotherapeutic drugs represent another class of drug
molecules that had been successfully delivered into PSMA-
positivehumanprostatecancercellsviatheaptamerA10[94,
95, 100]. Bagalkot et al. produced physical aptamer-doxo-
rubicin conjugates not requiring any chemical modiﬁcation
neitherofthedrugnoroftheaptamer[94](Figure 4).Doxo-
rubicin (Dox) can intercalate into the aptamer portion.
Dox is an anthracycline-derived drug molecule used in
chemotherapy to treat a wide range of cancers. Since this
treatment causes many side eﬀects, targeted delivery would
be desirable to decrease doses and associated cytotoxicities.
The authors studied in vitro binding and cell-speciﬁc uptake
of the physical conjugates by the PSMA-positive prostate
cancer cell line LNCaP to evaluate the targeted drug delivery.
A signiﬁcant reduction of the cell proliferation as well as en-
hanced cytotoxicity occurred in comparison to control cells
[94].
ThesamegroupimmobilizedthePSMA-speciﬁcaptamer
A10onthesurfaceofﬂuorescentquantumdots(QDs).Addi-
tionally, the A10-derivatized QDs were incubated with Dox
yielding QD-A10-Dox conjugates [97]( Figure 4). Although
not covalently linked, the aptamer-Dox-complex quenched
theﬂuorescenceoftheQDs.Whenincubatedwithtargetcells
these multifunctional nanoparticle conjugates de-livered
Dox into PSMA-positive cells. Cellular uptake could be
detected due to the recovered ﬂuorescence emission of the
QDs that subsequently stained the corresponding can-cer
cells. Additionally, Dox inhibited the growth of those cells.
In related approaches, superparamagnetic iron oxide
nanoparticles (SPION) or gold nanoparticles were derivatiz-
ed with A10 and Dox to create multifunctional nanoparticle
conjugatesforbothimagingandtreatmentofprostatecancer
cells [98, 99]. Each of the three parts of the conjugates had
a distinct function: the aptamer portion served as delivery
vehicle, the nanoparticle served as platform and imaging
agent in magnetic resonance imaging (MRI) or computer
tomography (CT), and Dox served as toxin (Figure 4).
The physical conjugates, however, were only able to carry
a limited amount of cargo molecules. A new strategy with
higher capacity was therefore developed by Bagalkot et al.
[94]. This group produced biocompatible and biodegradable
nanoparticles(NPs)derivedfrompoly(D,L-lactic-co-glycolic
acid)-block-poly(ethylene glycol) (PLGA-b-PEG) copoly-
mers. The surface of the NPs was coated with the PSMA-
speciﬁc aptamer A10. The authors encapsulated the anti-
mitotic chemotherapy drug docetaxel (Dtxl) into the NPs,
resulting in Dtxl-containing nanoparticle-aptamer biocon-
jugates (Dtxl-NP-Apt). Treating LNCaP prostate cancer cells
with Dtxl-NP-Apt led to a speciﬁc uptake by these cells and
furthermore to a signiﬁcant enhancement of cytotoxicity in
vitro in comparison to nanoparticles lacking A10. Intratu-
moral injection of the bioconjugates into LNCaP-derived
tumors in xenograft nude mice diminished tumor growth in
ﬁve out of seven mice.
Dhar et al. encapsulated the cisplatin prodrug Pt(IV)
within PLGA-PEG nanoparticles that were coated with the
PSMA aptamer A10 [100]( Figure 4). After cell-speciﬁc
uptake of the Pt(IV)-NP-Apt bioconjugates, Pt(IV) was
converted by cytosolic reduction processes into cisplatin.
Cytotoxicity assays with LNCaP cells revealed a higher in
vitro cytotoxic activity for the Pt(IV)-NP-Apt bioconjugates
with respect to free cisplatin or bioconjugates lacking the
aptamer portion. Additionally, the same laboratory recently
analyzed the pharmacokinetics, biodistribution, tolerability,
and eﬃciency of the Pt(IV)-NP-Apt bioconjugates when
administered in vivo in comparison to cisplatin [95]. The
authors observed a simultaneous improvement of all these
factors and proved the bioconjugates to be an eﬃcient
nontoxic item for chemotherapeutic treatment of human
prostate cancer.
6.3.2. Glycoprotein 120 (gp120). Envelope glycoprotein
gp160 of HIV-1, consisting of two parts, gp120 (glycoprotein
120) and gp41 (glycoprotein 41), respectively, plays a crucial
roleinHIV-1infection.Therefore,blockingHIV-1entryinto
T cells with the aid of corresponding aptamers seems to be
a therapeutically promising strategy. James et al. reported
the selection of 2 -F-modiﬁed RNA aptamers that bound
to gp120 with high aﬃnity, and thereby neutralized the in-
fectivity of R5 strains of HIV-1 in human peripheral blood
mononuclear cells (PBMCs) by blocking the interaction bet-
ween gp120 and CCR5 [69, 79, 80]. Zhou et al. published
in 2008 the application of these RNA aptamers [101]. The
authors designed aptamer-siRNA-chimeras that bound and
entered target cells via gp160-mediated endocytosis. The
siRNA portions were processed by dicer and speciﬁcally
downregulated the mRNA levels of the HIV-transcripts tat
and rev. This was the ﬁrst report on aptamer-siRNA-chimera
in which both parts inhibited HIV-1 functions.12 Journal of Nucleic Acids
One year later, the same group published the selection
of new 2 -F-modiﬁed gp120-binding aptamers that blocked
HIV-1 infection of cultured CEM T cells. Aptamers were
endocytosed into gp160-presenting target cells [102]. The
authors again took advantage of the cell-speciﬁc delivery
process of gp120-binding agents. Application of optimized
aptamer-siRNA-chimeras resulted in a successful downreg-
ulation of tat-a n drev-mRNAs, thereby reducing HIV-1 re-
plication and infectivity in PBMCs. Taken together, the anti-
gp120 aptamers may be promising agents for an anti-HIV
therapy due to their ability to inhibit HIV-1 infectivity and
replication or due to their potential to escort further drugs
into aﬀected cells.
6.3.3.Nucleolin. Nucleolin,amultifunctionaleukaryoticnu-
cleolar phosphoprotein, plays a pivotal role in RNA trans-
cription, in DNA replication, and in the regulation of
diﬀerent steps of ribosome biogenesis [111]. Furthermore
nucleolin binds to the mRNA of Bcl-2, an antiapoptotic
protein overproduced in several cancer types, and thereby
increasingitshalf-life[112].Nucleolinisoverproducedinthe
cytoplasm and on the plasma membrane of certain tumor
cells [113]. AS1411, a 26nt long nucleolin-binding DNA
aptamer, is taken up by nucleolin-presenting cancer cells
and prevents interaction of nucleolin with the mRNA of the
antiapoptotic Bcl-2. This causes destabilization of the Bcl-2
mRNA and subsequently a reduction of Bcl-2 protein which
may cause apoptosis [114]. Phase I and II clinical trials have
revealed the potency of AS1411 as new therapeutic agent
of diﬀerent cancer types, like relapsed or refractory acute
myeloid leukemia or renal cell carcinoma [113].
To further improve AS1411 functions, Shieh et al. tested
in 2010 whether AS1411 could deliver drugs to target cancer
cells for photodynamic therapy (PDT) [103]. They created
physical conjugates of AS1411 and TMPyP4 (5,10,15,20-
tetrakis(1-methylpyridinium-4-yl)porphyrin). TMPyP4 is a
photosensitizing porphyrin derivative that interacts with G-
quadruplexes. Intracellularly, it serves as potent inhibitor of
human telomerase [115]. The physical complex was escorted
into MCF7 breast cancer cells and normal endothelial M10
cells via aptamer-mediated delivery and caused TMPyP4
accumulation in MCF7 cells but not in M10 cells. Subse-
quently, both cell types were exposed to light. The MCF7
cells were damaged to a signiﬁcantly higher extent than
the control cells. These results underscore the potential of
AS1411 as a drug-delivery agent in cancer therapy.
6.3.4. Tyrosine-Protein Kinase-Like 7 Enzyme. Using cell-
SELEX, Shangguan et al. selected numerous diﬀerent apta-
mers that speciﬁcally recognized leukemia cells [54] (details
in cell-SELEX chapter). For the cell-SELEX experiment the
authors targeted cultured CCRF-CEM cells, a precursor cell
line of T cell acute lymphoblastic leukemia cells (ALL).
Ramos cells, a B cell line from human Burkitt’s lymphoma,
served for counter selection. Resulting aptamers speciﬁcally
recognizedCCRF-CEMcellswithhighaﬃnity.Furthermore,
target leukemia cells were identiﬁed when mixed with
patients’ human bone marrow aspirates. After identiﬁcation
of PTK7 (Tyrosine-protein kinase-like 7) as target molecule
of sgc8, Xiao et al. chose the aptamer sgc8c for further
cell-speciﬁc internalization studies [116]. Several drug-like
molecules were loaded on sgc8c, for instance, the MS2-coat
protein [117] or the chemotherapeutic agents daunorubicin
[118]a n dd o x o r u b i c i n[ 104]. A conjugate of the latter with
the aptamer sgc8 was particularly eﬃcient in selectively
killing speciﬁc cancer cells.
6.3.5. Transferrin Receptor (TfR). T h ee n z y m er e p l a c e m e n t
therapy (ERT) is a therapeutic application to replace an
absent or deﬁcient enzyme in patients by a functional
counterpart. ERT is used for example in lysosomal storage
diseases[119].Receptorsthatunderlieendocytosisarehighly
relevant for escort of these lysosomal enzymes into cells if
coupled to appropriate delivery vehicles like aptamers. One
of the mentioned receptors is TfR, ubiquitously presented
on mammalian cells. It directs iron to cells via binding of
transferrin-Fe3+, followed by cellular endocytosis and iron
release into the endosomes [120]. Chen et al. used both,
DNA and RNA aptamers, selectively binding to the mouse
transferrinreceptor(TfR)[105].RNAaptamersforTfRwere
ﬁrst coupled to streptavidin. The conjugates bound specif-
ically to mouse ﬁbroblasts (Ltk− cells) but not to human
293Tcells.Streptavidin couldbedetectedinthelysosomesof
Ltk− cells presumably due to cellular uptake via endocytosis.
After this proof of principle, a DNA aptamer was linked to
α-L-iduronidase, a lysosomal enzyme [105]. Cells lacking
this enzyme accumulate glycosaminoglycan. The aptamer-
enzyme conjugates were internalized into mouse ﬁbroblasts
deﬁcientforα-L-iduronidaseandmediatedbytheTfR-speci-
ﬁc DNA aptamer. The α-L-iduronidase was delivered into
lysosomes.Insidethelysosome,theenzymecouldcounteract
the glycosaminoglycan accumulation. The results reveal the
potency of aptamers to escort lysosomal enzymes into target
cells—a ﬁrst step towards an aptamer-mediated enzyme re-
placement therapy for lysosomal storage diseases [105].
6.3.6. Mucin-1 (MUC1). Mucin-1 (MUC1) is a glycopro-
tein with considerable O-glycosylation within its extracel-
lular domain. Membrane-associated glycoforms of MUC1
uniquely and abundantly line the cell surfaces of most epi-
thelial cells, for instance, eyes, lungs and intestines. MUC1
represents an important surface biomarker for early diagno-
sis of cancers [121, 122]. MUC1 tumor markers undergo re-
cycling processes, for instance, through endosomes. There-
fore, these cell surface proteins may serve as entry portals
for aptamers speciﬁcally binding to MUC1. Ferreira et al.
reported recently the selection of MUC1 binding DNA
aptamers using mimics of well-known MUC1 determinants
on cancer cells as target molecules [123]. The obtained
aptamers interacted speciﬁcally with cells presenting MUC1
glycosylation forms and were eﬃciently internalized by epi-
thelial cancer cells. Coupling the aptamers to prodrugs like
chlorin e6 (Ce6), a heme-like agent for photodynamic ther-
apy (PDT), selectively killed MUC1 presenting epithelial
cancer cell lines [106].
6.3.7. Epidermal Growth Factor Receptor (EGFR). The epi-
dermal growth factor receptor (EGFR) is a transmembraneJournal of Nucleic Acids 13
receptor with intrinsic tyrosine kinase activity. The EGFR
belongs to a family of receptors known as the ErbB family
(ErbB tyrosine kinase receptors). EGFR functions in a wide
range of cellular processes, including cell proliferation and
apoptosis [124]. It is overproduced in some types of cancer
cells [125]. EGFR is activated upon binding to its ligands,
for instance, EGF (epidermal growth factor) and TGFα
(transforming growth factor). Subsequently, EGFR changes
from an inactive monomeric form to an active homodimeric
form leading to autophosphorylation and signal transduc-
tion. EGFR activation triggers internalization processes
suggesting that receptor binding aptamers could become
cointernalized, and thus serve as drug-delivery tools [126].
Li et al. reported in 2010 on the selection and application of
aptamers that bind speciﬁcally to EGFR [107]. The authors
generatedconjugatesofaptamersandgoldnanoparticlesthat
speciﬁcally targeted EGFR presenting A431 cells. The A431
cells internalized the aptamer-coated gold nanoparticles via
EGFR-mediatedendocytosis.Presumably,theseaptamersare
suitable for the delivery of further cargo molecules into
EGFR presenting cells.
6.3.8. Immunglobulin M Heavy Chain. In 2007, Tang et al.
reported on the cell-based systematic evolution of aptamers
binding whole living cells [127]. Ramos cells, a B-cell
Burkitt’s lymphoma cell line, served as target in the cell-
SELEX process. Resulting aptamers were able to identify
Ramos cells within a complex biological mixture [127].
On the basis of this work, Mallikaratchy et al. identiﬁed
membrane protein targets that were bound by the Ramos
cell-speciﬁc aptamers [128]. By covalently cross-linking the
Ramos cell-speciﬁc aptamer TD05 to its target cells, the
authors could identify the molecular target of TD05 using
mass spectrometry: the membrane bound IgM heavy chain.
ItispartoftheB-cellreceptorandpresentedinhighamounts
on the surface of Burkitt’s lymphoma cells. Internalization of
the aptamer, however, was not shown.
Nevertheless, converting these aptamers into delivery
agents Wu et al. published a novel approach by modifying
the end of an aptamer with a hydrophobic tail [108]. This
resulted in the assembly of highly ordered micelle-like nano-
particles.
These aptamer-containing nanoparticles showed lower
oﬀ rates after binding to the Ramos cellsat 37◦C, presumably
due to multivalency. Furthermore, assembly of the aptamers
to micelles allows them to enter their target cells by fusion of
the micelle with the membrane of target cells. Loading the
micelles with drugs could thus yield drug delivery agents.
Additionally, the authors mimicked blood circulation of
living organisms in a ﬂow channel system. The aptamer-
micelles were still able to recognize their target under ﬂow
conditions. These results might pave the way for further
applications of aptamer-micelles as drug-delivery vehicles in
a biological living system.
7. Conclusions
Since the invention of the SELEX process more than two
decades ago, considerable progress has been made in the
ﬁeld of aptamer technology. Several improvements, most
importantly automation, have made the traditional SELEX
procedurefasterandmoreeﬃcientandaptamersmoreeasily
available. Aptamers for all kinds of targets, ranging from
small molecules to cell surface receptors have successfully
been selected. Today, the selection of aptamers for whole
cells is becoming increasingly popular, because their ability
to speciﬁcally recognize subpopulations of cells is highly
soughtafter.Weanticipatethatrecenttechnicaladvanceswill
further boost this trend. In particular, the use of FACS in
the selection step represents a major technical progress, as it
allowsselectingaptamersandremovingselection-hampering
dead cells simultaneously.
The characteristics of aptamers also make them promis-
ing tools for diagnostic applications. Aptamer-based arrays,
for example, could become a valuable alternative to anti-
body-based microarrays for protein production proﬁling of
whole cells. These aptamer arrays might also be used to iden-
tify a speciﬁc cell type in complex cell mixtures. However,
more time and scientiﬁc eﬀort will still be required before
aptamer-based products for diagnostics will be routinely
applied.
Aptamers also have numerous properties that render
them promising tools in therapy. As reviewed in this paper,
there are aptamers for a large variety of cell-speciﬁc target
molecules that play crucial roles in diseases, like viral
infection, inﬂammation, and cancer. We have summarized
examples from the recent literature illustrating aptamers
that inhibit or activate cellular functions. Furthermore, we
outlined how aptamers have been used to deliver therapeutic
agents, such as chemotherapeutics, siRNAs or nanoparticles
to cells or tissues. Aptamers are formidable delivery tools,
becausetheyarecomparativelysmallandcaneasilypenetrate
tissues or become cointernalized with the receptors they are
speciﬁcally binding to. Furthermore, aptamers can be tuned
for desired applications: modiﬁed bases can be integrated to
increase the in vivo stability or to regulate their in vivo func-
tion. The possibility to regulate and control the function of
aptamers is crucial for a deﬁned application in therapy. In
this ﬁeld, we expect further developments based on light
regulation of aptamers as has been demonstrated by caged
aptamers for human thrombin [129]. Another promising
approach is the use of activatable [130] and deactivatable
[129] aptamer probes (AAP) for the targeting of membrane
proteins of living cancer cells [131].
Most of the diagnostically und therapeutically relevant
aptamers mentioned in this paper have so far only been
tested in animal models. There is only a limited number
of clinical investigations of aptamers for therapeutic appli-
cations in humans. Some of these aptamers are binding
speciﬁcally to deﬁned proteins in cancer and eye diseases.
However, even if there is only one FDA-approved aptamer-
based drug so far (Macugen), some additional aptamers
have already entered the phase of clinical trials. This is not
very astonishing, because it often takes more than 10 years
beforeadrugcandidatebecomescommerciallyavailable.The
timeline for the development of aptamers as commercial
therapeutics is comparable to the generation of antibody-
based drugs. In 1975, the ﬁrst monoclonal antibodies were14 Journal of Nucleic Acids
generated. In 1986, the ﬁrst monoclonal antibody was
approved by the FDA for therapeutically application the
second one in 1994. The same holds true for aptamers—
in 1990, the ﬁrst aptamers were selected, in 2004, the ﬁrst
aptamer-based drug, Macugen, was approved by the FDA.
Finally, the selection of aptamers and their use in diag-
nostic and therapeutic applications is still an expanding area.
Presumably,inthenearfuture,furtheraptamersmaybecome
approved drugs.
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